Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

• Autor(a) principal: Sadoff, Jerald
• Data de Publicação: 2021
• Outros Autores: Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Fennema, Hein, Spiessens, Bart, Offergeld, Kim, Scheper, Gert, Taylor, Kimberly L., Robb, Merlin L., Treanor, John, Barouch, Dan H., Stoddard, Jeffrey, Ryser, Martin F., Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Cauwenberghs, Nancy, Tanner, Tamzin, Hardt, Karin, Ruiz-Guiñazú, Javier, Gars, Mathieu Le, Schuitemaker, Hanneke, Hoof, Johan Van, Struyf, Frank, Douoguih, Macaya, ENSEMBLE Study Group
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
• Texto Completo: https://www.arca.fiocruz.br/handle/icict/50454
• topic: COVID-19; SARS-CoV-2; Vaccine; Ad26.COV2.S

Beatriz Grinsztejn - Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, G. Scheper, M.L.G., H.S., J.V.H., M.D.); South African Research Council, Cape Town, South Africa (G.G.); Janssen Research and Development, Beerse, Belgium (A.V., C.T., H.F., B.S., K.O., M.F.R., N.C., T.T., K.H., J.R.G., F.S.); Janssen Research and Development, Spring House, PA (V.C.); Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro (B.G.); the University of Alabama at Birmingham, Birmingham (P.A.G.); the National Institute of Allergy and Infectious Diseases, Rockville (K.L.T., M.A.M.), Walter Reed Army Institute of Research, Silver Spring (M.L.R.), and the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (K.M.N.) - all in Maryland; Biomedical Advanced Research and Development Authority, Washington, DC (J.T.); the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston (D.H.B.); Janssen Research and Development, Raritan, NJ (J. Stoddard); and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle (L.C.).